According to Acceleron Pharma's latest financial reports the company's current revenue (TTM) is $0.11 B. In 2020 the company made a revenue of $92.52 M an increase over the years 2019 revenue that were of $73.99 M.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2021 (TTM) | $0.11 B | 21.88% |
2020 | $92.52 M | 25.05% |
2019 | $73.99 M | 428.85% |
2018 | $13.99 M | 3.78% |
2017 | $13.48 M | -51.45% |
2016 | $27.77 M | 53.47% |
2015 | $18.09 M | 23.68% |
2014 | $14.63 M | -74.43% |
2013 | $57.22 M | 275.17% |
2012 | $15.25 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | $93.02 B | 82,392.64% | ๐บ๐ธ USA |
Pfizer PFE | $58.49 B | 51,775.60% | ๐บ๐ธ USA |
Amgen AMGN | $28.19 B | 24,899.11% | ๐บ๐ธ USA |
Regeneron Pharmaceuticals REGN | $13.11 B | 11,532.44% | ๐บ๐ธ USA |
Sangamo Therapeutics
SGMO | $0.17 B | 56.28% | ๐บ๐ธ USA |
Onconova Therapeutics ONTX | $0.22 M | -99.80% | ๐บ๐ธ USA |
bluebird bio
BLUE | $21.72 M | -80.73% | ๐บ๐ธ USA |